Teladoc Inc. (TDOC) Cut to “Sell” at Zacks Investment Research
According to Zacks, “Teladoc has incurred significant losses in each quarter since 2013. As of Dec 31, 2015, it had an accumulated deficit of $130.5 million. These losses pertain to substantial investments made for growth. For full-year 2016, it is expected to report a net loss per share of $1.47 to $1.52. Nevertheless, the company is witnessing steady business growth with insurers and customers increasingly embracing telehealth. Teladoc’s organic growth initiative remains on track. With four acquisitions completed since its inception, the insurer has expanded its distribution capabilities and broadened its service offering. Its buyout of HealthiestYou is expected to further solidify its leadership position. The company also boasts an impressive clientele.”
TDOC has been the topic of a number of other research reports. Stifel Nicolaus began coverage on Teladoc in a report on Wednesday, June 1st. They set a hold rating on the stock. Jefferies Group reaffirmed an outperform rating and set a $25.00 target price on shares of Teladoc in a report on Tuesday, May 31st. Piper Jaffray Cos. reaffirmed an overweight rating and set a $21.00 target price (down previously from $22.00) on shares of Teladoc in a report on Friday, August 5th. FBR & Co reaffirmed a buy rating on shares of Teladoc in a report on Sunday, August 28th. Finally, Oppenheimer Holdings Inc. reaffirmed an outperform rating and set a $24.00 target price (down previously from $25.00) on shares of Teladoc in a report on Friday, August 5th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have issued a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus target price of $22.90.
Shares of Teladoc (NYSE:TDOC) opened at 18.95 on Tuesday. The stock’s market capitalization is $866.11 million. The company has a 50 day moving average price of $17.99 and a 200-day moving average price of $13.99. Teladoc has a 1-year low of $9.08 and a 1-year high of $24.50.
Teladoc (NYSE:TDOC) last issued its quarterly earnings results on Wednesday, August 3rd. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.01. The firm earned $26.50 million during the quarter, compared to the consensus estimate of $28.20 million. Teladoc had a negative return on equity of 33.97% and a negative net margin of 60.88%. Teladoc’s revenue for the quarter was up 44.9% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.46) earnings per share. On average, equities research analysts forecast that Teladoc will post ($1.45) EPS for the current fiscal year.
In other news, insider Adam C. Vandervoort sold 52,865 shares of Teladoc stock in a transaction on Monday, August 8th. The stock was sold at an average price of $16.64, for a total transaction of $879,673.60. Following the transaction, the insider now directly owns 46,685 shares in the company, valued at approximately $776,838.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director James K. Outland sold 10,000 shares of Teladoc stock in a transaction on Wednesday, June 29th. The shares were sold at an average price of $15.00, for a total value of $150,000.00. Following the transaction, the director now owns 59,089 shares in the company, valued at $886,335. The disclosure for this sale can be found here. Insiders own 5.94% of the company’s stock.
Several institutional investors have recently modified their holdings of TDOC. US Bancorp DE boosted its position in shares of Teladoc by 31.7% in the second quarter. US Bancorp DE now owns 7,507 shares of the company’s stock valued at $120,000 after buying an additional 1,805 shares during the period. UBS Asset Management Americas Inc. bought a new stake in Teladoc during the first quarter valued at $106,000. American International Group Inc. raised its stake in Teladoc by 109.4% in the second quarter. American International Group Inc. now owns 11,945 shares of the company’s stock valued at $191,000 after buying an additional 6,240 shares in the last quarter. Airain ltd bought a new stake in Teladoc during the second quarter valued at $200,000. Finally, DORCHESTER WEALTH MANAGEMENT Co bought a new stake in Teladoc during the second quarter valued at $240,000. Institutional investors own 40.45% of the company’s stock.
Teladoc, Inc, together with its subsidiaries, is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company operates through health services segment. Its solution connects its Members, with its over 3,000 board-certified physicians and behavioral health professionals who treat a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related companies with MarketBeat.com's FREE daily email newsletter.